The company said it will use the financing to support the commercialization of its automated biological testing platform for academic and clinical research.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The German firm grew revenues to €5.3 million for the first nine months of the year from €976,000 a year ago, but its net loss expanded 48 percent year over year.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.
